NAALADL2-AS3

Across TCGA pan-cancer cohorts, NAALADL2-AS3 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of NAALADL2-AS3’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where NAALADL2-AS3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NAALADL2-AS3 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

STAD, COAD, and LUAD are the cancer types where NAALADL2-AS3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NAALADL2-AS3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.085	.003	4	view →
COAD	Female	All	−0.044	.018	3	view →
LUAD	All	III,IV	+0.120	.023	1	view →
THCA	Female	All	−0.041	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

NAALADL2-AS3–STAD

Open the STAD breakdown →